Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance

Table 1 Clinical trials on the combination of poly(ADP-ribose) polymerase inhibitor with chemotherapy and immunotherapy

Identifier	Phase	iPARP	Title	Status
NCT04548752	II	Olaparib	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations	Recruiting
NCT02890355	II	Veliparib	Randomized Phase II Study of 2nd Line FOLFIRI vs Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer	Active, not recruiting
NCT01585805	II	Veliparib	A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with Pancreas Adenocarcinoma and known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)	Active, not recruiting
NCT01489865	I/II	ABT-888	A Phase I/II Study of ABT-888 in combination with 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients with Metastatic Pancreatic Cancer	Active, not recruiting
NCT03404960	I/II	Niraparib + Nivolumab Niraparib + Ipilimumab	PARPVAX: A Phase 1b/2, Open Label Study of Niraparib Plus either Ipilimumab or Nivolumab in Patients with Advanced Pancreatic Cancer whose disease has not progressed on Platinum-based Therapy	Recruiting
NCT03553004	II	Niraparib	Niraparib in Metastatic Pancreatic Cancer after previous Chemotherapy (NIRA-PANC)	Recruiting

iPARP: Poly(ADP-ribose) polymerase inhibitor.